Boston Scientific Dirección

Dirección controles de criterios 3/4

El CEO de Boston Scientific es Mike Mahoney , nombrado en Oct 2011, tiene una permanencia de 13.08 años. compensación anual total es $18.72M, compuesta por 7.5% salario y 92.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de MX$3.14B. La antigüedad media del equipo directivo y de la junta directiva es de 8.6 años y 8.3 años, respectivamente.

Información clave

Mike Mahoney

Chief Executive Officer (CEO)

US$18.7m

Compensación total

Porcentaje del salario del CEO	7.5%
Permanencia del CEO	13.1yrs
Participación del CEO	0.1%
Permanencia media de la dirección	8.6yrs
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Mahoney en comparación con los beneficios de Boston Scientific?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$19m	US$1m	US$2b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$861m
Mar 31 2023	n/a	n/a	US$846m
Dec 31 2022	US$17m	US$1m	US$642m
Sep 30 2022	n/a	n/a	US$596m
Jun 30 2022	n/a	n/a	US$828m
Mar 31 2022	n/a	n/a	US$754m
Dec 31 2021	US$16m	US$1m	US$985m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$526m
Mar 31 2021	n/a	n/a	US$201m
Dec 31 2020	US$14m	US$667k	-US$115m
Sep 30 2020	n/a	n/a	US$4b
Jun 30 2020	n/a	n/a	US$4b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$16m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$14m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$670m
Jun 30 2018	n/a	n/a	US$521m
Mar 31 2018	n/a	n/a	US$112m
Dec 31 2017	US$13m	US$1m	US$104m

Compensación vs. Mercado: La compensación total de Mike($USD18.72M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD5.73M).

Compensación vs. Ingresos: La compensación de Mike ha sido consistente con los resultados de la empresa en el último año.

CEO

Mike Mahoney (59 yo)

13.1yrs

Permanencia

US$18,723,735

Compensación

Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Mahoney	Chairman	13.1yrs	US$18.72m	0.12% MX$ 3.1b
Daniel Brennan	Executive VP & CFO	10.8yrs	US$5.83m	0.015% MX$ 406.8m
Joseph Fitzgerald	Executive VP & Group President of Cardiology	14.8yrs	US$5.59m	0.011% MX$ 300.5m
Jeffrey Mirviss	Executive VP & President of Peripheral Interventions	11.8yrs	US$3.78m	0.0019% MX$ 50.9m
Arthur Crosswell Butcher	Executive VP and Group President of MedSurg & Asia Pacific	8.3yrs	US$4.27m	0.0016% MX$ 43.9m
John Sorenson	Executive Vice President of Global Operations	2.5yrs	sin datos	0.0025% MX$ 67.5m
Emily Woodworth	Senior VP	less than a year	sin datos	0.00026% MX$ 7.0m
Jodi Eddy	Senior VP and Chief Information & Digital Officer	8.9yrs	sin datos	sin datos
Jonathan Monson	Senior VP of Investor Relations	less than a year	sin datos	0.0026% MX$ 69.1m
Vance Brown	Senior VP	3.4yrs	sin datos	0.0023% MX$ 62.4m
Mary Moynihan	Senior VP of Market Access & Chief Marketing Officer	3.5yrs	sin datos	sin datos
Wendy Carruthers	Executive Vice President of Human Resources	11.9yrs	sin datos	0.0022% MX$ 58.1m

8.6yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BSX * es experimentado (8.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Mahoney	Chairman	12yrs	US$18.72m	0.12% MX$ 3.1b
Edward Ludwig	Lead Independent Director	10.7yrs	US$360.00k	0.0030% MX$ 80.3m
Ellen Zane	Independent Director	8.6yrs	US$335.00k	0.0033% MX$ 88.1m
Yoshiaki Fujimori	Independent Director	8.3yrs	US$320.00k	0.00020% MX$ 5.4m
David Wichmann	Independent Director	3.4yrs	US$338.75k	0.0027% MX$ 71.8m
Cheryl Pegus	Director	less than a year	sin datos	sin datos
David Habiger	Director	less than a year	sin datos	0.00024% MX$ 6.4m
Charles Dockendorff	Independent Director	9.6yrs	US$326.25k	0.0043% MX$ 114.4m
John Sununu	Independent Director	15.6yrs	US$340.00k	0.0036% MX$ 95.6m
Jessica Mega	Independent Director	1.4yrs	US$233.23k	0.00042% MX$ 11.2m
Susan Morano	Independent Director	1.4yrs	US$233.23k	0.00027% MX$ 7.2m

8.3yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de BSX * se considera experimentada (8.3 años de antigüedad promedio).

Boston Scientific Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Boston Scientific Corporation Elects David Habiger to Board of Directors

Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors

Boston Scientific Corporation, Annual General Meeting, May 02, 2024

Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024

Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation

Insufficient new directors

Recent updates

Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Now 24% overvalued after recent price rise

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Cortex, Inc. from Ajax Health.

Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Cortex EP from Ajax Health.

Third quarter 2024 earnings released: EPS: US$0.32 (vs US$0.34 in 3Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Now 22% overvalued after recent price rise

Boston Scientific Corporation Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Corporation to Report Q3, 2024 Results on Oct 23, 2024

Boston Scientific Corporation Receives Japanese Regulatory Approval for the Farapulse™ Pulsed Field Ablation System

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Silk Road Medical, Inc (NasdaqGS:SILK) from a group of shareholders.

Boston Scientific Corporation Elects David Habiger to Board of Directors

Second quarter 2024 earnings released: EPS: US$0.22 (vs US$0.18 in 2Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal Year 2024

Boston Scientific Corporation to Report Q2, 2024 Results on Jul 24, 2024

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors

First quarter 2024 earnings released: EPS: US$0.34 (vs US$0.21 in 1Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Boston Scientific Corporation to Report Q1, 2024 Results on Apr 24, 2024

New minor risk - Shareholder dilution

Boston Scientific Corporation, Annual General Meeting, May 02, 2024

Full year 2023 earnings released: EPS: US$1.08 (vs US$0.45 in FY 2022)

Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024

Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2024

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Boston Scientific Corporation to Report Q4, 2023 Results on Jan 31, 2024

Boston Scientific Corporation Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Relievant Medsystems, Inc.

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.12 in 3Q 2022)

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal AGENT IDE Clinical Trial of the AGENT™ Drug-Coated Balloon

Boston Scientific Corporation Provides Earnings Guidance for the Full Year 2023

Boston Scientific Corporation Announces FDA Approval for the Latest-Generation watchMAN FLX Pro Left Atrial Appendage Closure Device

Boston Scientific Corporation to Report Q3, 2023 Results on Oct 26, 2023

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal Advanced Clinical Trial of the FARAPULSE™ Pulsed Field Ablation System

Second quarter 2023 earnings released: EPS: US$0.18 (vs US$0.17 in 2Q 2022)

Boston Scientific Corporation Receives FDA Approval for the POLARx™ Cryoablation System

Boston Scientific Corporation (NYSE:BSX) agreed to acquire EV Business and B Braun of Aesculap AG for €47 million.

Boston Scientific Corporation to Report Q2, 2023 Results on Jul 27, 2023

Insufficient new directors

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of an additional stake in M.I.TECH Co.,Ltd (KOSDAQ:A179290) from Synergy Innovation Co., Ltd. (KOSDAQ:A048870)

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Insufficient new directors

Insider recently sold Mex$11m worth of stock

Boston Scientific Corporation Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System

Full year 2022 earnings released: EPS: US$0.45 (vs US$0.69 in FY 2021)

Boston Scientific Corporation Provides Earnings Guidance for First Quarter of 2023 and Full Year 2023

Boston Scientific Corporation, Annual General Meeting, May 04, 2023

Insufficient new directors

Boston Scientific Corporation to Report Q4, 2022 Results on Feb 01, 2023

Independent Director recently sold Mex$16m worth of stock

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Insufficient new directors

Boston Scientific Corporation Announces the First Results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) Study

Boston Scientific Corporation announced that it expects to receive funding from BeWeld Medical Ltd.

Boston Scientific Corporation Announces Impairment Results for the Three Months Ended September 30, 2022

Third quarter 2022 earnings released: EPS: US$0.12 (vs US$0.28 in 3Q 2021)

Boston Scientific Corporation to Report Q3, 2022 Results on Oct 26, 2022

Boston Scientific Announces Results from the PROTECTED TAVR Clinical Trial

Boston Scientific Corporation Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

Insufficient new directors

Boston Scientific Corporation acquired Obsidio, Inc.